The 5 best face masks for great summer skin
Reviews and recommendations are unbiased and products are independently selected. Postmedia may earn an affiliate commission from purchases made through links on this page.
Article content
After a summer of (hopefully) sun, sand and sea, your skin is probably calling for a reset — and a face mask is the ultimate easy fix.
Article content
Article content
Whether you're craving a formula to restore hydration or a cooling version to help refresh your visage after a long weekend in the sun, these masks help calm redness, balance oil and restore radiance.
Article content
Article content
Whether it's out-there ingredients such as snail mucin, seven- or 10-step regimens, or its pioneering treatments, Korean beauty is a major thing. For the first-time curious or the very well-versed, The K Shop is a great resource for discovering the latest and greatest — as well as some perennial bestsellers. For skin dulled by the heat of summer, try the Radiant Vita Niacinamide Real Deep Mask by Biodance, a sheet mask that can actually be worn overnight for maximum revitalizing effect.
Article content
Widely touted for its ability to boost skin cell and collagen production, which in turn helps unclog pores, exfoliate skin and give it a fresher, plumper look overall, retinol is one of the most common ingredients in antiaging skin care, and this Ageless+ Retinol Overnight Masque with 0.5 per cent retinol complex has just enough in it to do great work while you catch some zzzs. Unlike some formulas, it's also safe enough to use every night, so there's no need to keep track of whether you already applied it the night before — because really, who has the energy for that when you're getting ready for bed?
Article content
Article content
Article content
Proudly founded in the U.K. and now Canadian-owned, The Body Shop has been our decades-long go-to for no-frills skin care that smells good and does the trick, no matter your age or skin care concern. Case in point? This Aloe Soothing Sheet Mask, which has a nice, light cucumber-y scent thanks to cucumber extract and aloe vera, and hydrates and calms dry, sensitive skin in just 15 minutes.
Article content
It might seem expensive for a single, throwaway mask — and if we're totally honest, we don't love the disposability of sheet masks, though their convenience and hygiene factor is undeniable, especially when travelling — but this deeply moisturizing mask by Japanese skin care brand Tatcha is worth it. Packed with hyaluronic acid and red algae, and without any parabens, phthalates, urea or other sometimes-problematic ingredients, it's an ideal 15-minute treat for August skin.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Market Online
2 hours ago
- The Market Online
U.S. federal cannabis rescheduling: A game-changer for Canopy Growth?
The U.S. government is considering reclassifying cannabis from Schedule I to Schedule III, which would recognize its medical benefits, ease research restrictions, and offer tax relief to cannabis businesses Through its Canopy USA structure, Canopy Growth holds stakes in major U.S. cannabis companies like Acreage Holdings, Wana Brands, and Jetty, positioning itself to capitalize on federal policy changes Canopy Growth reported a 43 per cent year-over-year increase in Canadian adult-use cannabis revenue in Q1 FY2026, signaling operational momentum as it prepares for potential U.S. market expansion Canopy Growth stock (TSX:WEED) last traded at C$2.08 The United States could be on the cusp of a transformative shift in federal cannabis policy. Recent statements from President Donald Trump and widespread media coverage confirm that the administration is currently reviewing a proposal to reclassify cannabis from a Schedule I to a Schedule III controlled substance. This content has been prepared as part of a partnership with Canopy Growth Corp. and is intended for informational purposes only. This reclassification would mark the most significant federal policy change in over 50 years, formally acknowledging cannabis's medical utility and opening new avenues for research, patient access, and industry growth. Currently, cannabis is classified alongside heroin and LSD under Schedule I, a category reserved for substances with no accepted medical use and high abuse potential. Moving it to Schedule III—alongside drugs like ketamine and anabolic steroids—would signal a federal recognition of its therapeutic potential and reduce regulatory burdens. Implications of Schedule III reclassification If cannabis is reclassified, the following changes are expected: Medical recognition : Cannabis would be federally acknowledged as having medical benefits, aligning U.S. policy more closely with countries like Canada, Germany, and Australia. : Cannabis would be federally acknowledged as having medical benefits, aligning U.S. policy more closely with countries like Canada, Germany, and Australia. Expanded research : Researchers would gain broader access to cannabis products for clinical trials, overcoming the restrictive barriers imposed by Schedule I classification. : Researchers would gain broader access to cannabis products for clinical trials, overcoming the restrictive barriers imposed by Schedule I classification. Tax relief: Cannabis businesses would no longer be subject to Section 280E of the IRS tax code, which currently prevents them from deducting ordinary business expenses. This could significantly improve profitability across the sector. Regulatory clarity: While not full legalization, Schedule III status would provide a more stable regulatory environment, encouraging institutional investment and broader market participation. With the U.S. retail cannabis market projected to reach approximately US$50 billion by 2026, the stakes are … high. Canopy Growth: Positioned for U.S. expansion Canopy Growth Corp. (TSX:WEED, NASDAQ:CGC) has positioned itself to capitalize on the evolving U.S. cannabis landscape through its Canopy USA structure. This unconsolidated, non-controlling entity holds a portfolio of U.S. cannabis assets, including: Acreage Holdings, Inc. – A vertically integrated multi-state operator with a strong presence in the Northeast and Midwest. – A vertically integrated multi-state operator with a strong presence in the Northeast and Midwest. Wana Brands – An edibles company. – An edibles company. Jetty (Lemurian, Inc.) – A California-based producer of premium cannabis extracts and vape technology. – A California-based producer of premium cannabis extracts and vape technology. The Cima Group and Wana Wellness – Expanding Canopy's reach into wellness and lifestyle segments. This structure allows Canopy to maintain compliance with U.S. federal regulations while retaining exposure to the upside of U.S. market growth. Shareholders recently approved the creation of a new class of exchangeable shares; a move designed to accelerate Canopy's U.S. market entry and enhance flexibility. Financial momentum and solid readiness Canopy Growth's Q1 FY2026 results reflect a company regaining momentum: Canada adult-use cannabis net revenue rose 43 per cent year-over-year to C$27 million , driven by strong demand for new products like Claybourne infused pre-rolls. rose to , driven by strong demand for new products like Claybourne infused pre-rolls. Total cannabis revenue increased 24% , while consolidated net revenue grew 9 per cent to C$72.1 million . increased , while consolidated net revenue grew to . The company achieved CA$17 million of its CA$20 million annualized cost savings target and reduced SG&A expenses by 21 per cent. CEO Luc Mongeau emphasized the company's focus on high-demand product categories and retail distribution, while interim CFO Tom Stewart highlighted ongoing efforts to improve gross margins and operational efficiency, stating, 'Our financial discipline has already delivered meaningful operating expense reductions, and we see further opportunity to simplify and focus the business. Improving gross margin remains a key priority while maintaining topline performance in all areas of the business.' Investor takeaway: A catalyst for revaluation The potential rescheduling of cannabis to Schedule III could be a major catalyst for Canopy Growth and the broader cannabis sector. For Canopy, it would: Unlock tax savings and improve cash flow. Enable deeper integration of its U.S. assets under Canopy USA. Attract institutional investors previously deterred by regulatory uncertainty. Accelerate revenue growth in the world's largest cannabis market. While regulatory timelines remain uncertain, the momentum is clearly building. For investors, Canopy Growth represents a well positioned, financially disciplined player ready to seize the opportunities of a rescheduled U.S. cannabis market. About Canopy Growth Canopy Growth Corp. delivers products with a focus on premium and mainstream cannabis brands, in addition to vaporizer technology made in Germany. Canopy Growth stock (TSX:WEED) last traded around 8 per cent lower at C$2.08 on the TSX. Though it has risen 10 per cent since June, it has lost 47 per cent since the year began and 78 per cent since this time last year. On the NASDAQ, CGC stock also finished 8 per cent lower at US$1.50. It has risen more than 12 per cent since June but has lost 45 per cent since the year began and is 78 per cent lower since this time last year. Join the discussion: Find out what the Bullboards are saying about Canopy Growth and check out Stockhouse's stock forums and message boards. Stockhouse does not provide investment advice or recommendations. All investment decisions should be made based on your own research and consultation with a registered investment professional. The issuer is solely responsible for the accuracy of the information contained herein. For full disclaimer information, please click here .
Cision Canada
16 hours ago
- Cision Canada
Prescientx Ushers in Canada's New Era of Engineered Infection Prevention
WATERLOO, ON, /CNW/ - As Canadian healthcare facilities face rising disease transmission and new national infection control standards, IPC Technologies Inc. (operating as Prescientx) announces exclusive Canadian healthcare distribution rights for a suite of advanced Engineered Infection Prevention (EIP) technologies. Prescientx is uniquely positioned to help hospitals and healthcare construction partners meet and exceed the new CSA Z8000 and Z317.12 standards—critical for compliance and Ministry of Health funding across several provinces. The new standards address critical vulnerabilities in healthcare: the need for continuous upper air disinfection, continuous surface disinfection, continuous sink disinfection and automatic whole room disinfection. Prescientx's technologies can achieve up to a 100-fold reduction in exposure to pathogens, continuously and automatically, representing a monumental leap in patient and staff safety designed to significantly reduce Healthcare Acquired Infections (HAIs). "The conversation around infection control in Canada has fundamentally changed," said Keith Hunt, President of Prescientx. "It's no longer just about daily disinfection; it's about engineering for continuous protection. The new CSA standards require a level of verifiable, engineered performance – pathogen reduction that provides a cost-benefit that daily disinfection simply cannot provide. Most importantly, they mandate EIP-qualified personnel to advise and oversee these systems. Our entire business is structured to meet this exact moment." Prescientx's exclusive portfolio includes: ASEPT-1X MAX ™ by Sanuvox – A Health Canada PMRA approved engineered patented UVC system for creating fully automated, self-disinfecting rooms in Canada. SmartFLO3 ™ by Franke – A splashless CSA-compliant self-cleaning and disinfecting, biofilm-free sink system, engineered for compatibility with UV disinfection. Sanilume by iLLUMiSoft Lighting – A Health Canada PMRA approved optimized, high-output Upper Air GUV solution, providing continuous air disinfection designed to reduce exposure to airborne pathogens to near zero levels. EOScu surfaces & Aereus copper coatings – self-disinfecting surfaces like overbed tables, countertops, bedrails, fixtures and hardware that rapidly and continually reduce pathogens on epidemiologically important, high touch surfaces. This announcement solidifies the company's strategic business model, which shed its former manufacturing arm to focus exclusively on the professional services and specialized distribution required by today's market. "Our identity has always been rooted in providing automated solutions to reduce Healthcare Acquired Infections through engineering expertise," Hunt added. "Our focused model allows us to be true, unbiased partners to IPAC Professionals, Hospital Contractors, and Facility Managers. We de-risk their projects by ensuring the solutions are not only compliant from day one but are also integrated correctly for long-term reliability and provide a stunning return on investment. We have shown payback periods as short as 23 days." Prescientx urges healthcare stakeholders to assess their readiness for the new CSA standards and explore engineered solutions that deliver continuous protection and measurable outcomes. About Prescientx Inc. Canada.
Ottawa Citizen
17 hours ago
- Ottawa Citizen
Wiggin: Fortunately, the PSA test helped detect my prostate cancer in time
Ottawa resident Michael Wiggin is undergoing treatment at the Ottawa Hospital's Cancer Centre for prostate cancer. Photo by JULIE OLIVER / Postmedia Mohammed Adam's Aug. 7 article is important for the facts it raises and its contribution to lessening the fear of prostate cancer. But I offer caution and recommend vigilance. THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY Subscribe now to read the latest news in your city and across Canada. Exclusive articles from Elizabeth Payne, David Pugliese, Andrew Duffy, Bruce Deachman and others. Plus, food reviews and event listings in the weekly newsletter, Ottawa, Out of Office. Unlimited online access to Ottawa Citizen and 15 news sites with one account. Ottawa Citizen ePaper, an electronic replica of the print edition to view on any device, share and comment on. Daily puzzles, including the New York Times Crossword. Support local journalism. SUBSCRIBE TO UNLOCK MORE ARTICLES Subscribe now to read the latest news in your city and across Canada. Exclusive articles from Elizabeth Payne, David Pugliese, Andrew Duffy, Bruce Deachman and others. Plus, food reviews and event listings in the weekly newsletter, Ottawa, Out of Office. Unlimited online access to Ottawa Citizen and 15 news sites with one account. Ottawa Citizen ePaper, an electronic replica of the print edition to view on any device, share and comment on. Daily puzzles, including the New York Times Crossword. Support local journalism. REGISTER / SIGN IN TO UNLOCK MORE ARTICLES Create an account or sign in to continue with your reading experience. Access articles from across Canada with one account. Share your thoughts and join the conversation in the comments. Enjoy additional articles per month. Get email updates from your favourite authors. THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK. Create an account or sign in to continue with your reading experience. Access articles from across Canada with one account Share your thoughts and join the conversation in the comments Enjoy additional articles per month Get email updates from your favourite authors I am one of those who had PSA tests as part of normal blood tests and was able to see trends. I went from too frequent peeing at night, to prostate enlargement, to upward-trending PSA levels, to a biopsy and then cancer detection. I was fortunate that, while advanced, it was still contained within the prostate. The cancer had not spread or metastasized. High-dose radiation (brachytherapy) was proposed, followed by extended lower-dose radiation for about 20 days. If the cancer had spread, I would have been in for chemotherapy – a whole different experience with different probabilities of cancer management or cure. As it is, early detection of contained prostate cancer has a very high success rate. I am thankful for early detection by medical staff and for our healthcare system, where treatment is free. With better awareness, people may not have the stress and fear that Mohammed alluded to. I have friends or acquaintances who have died from prostate cancer and those who have been treated and now live a normal and productive life. Some have elevated PSA levels, but no biopsy detected cancer and some, like me, showed growing PSA levels and cancer present. While Mohammed's article is right to lessen fear of prostate cancer, it may lead to an 'ignorance-is-bliss' attitude, leading to delayed detection and greater stress and pain for individuals and costs to our healthcare system. Having just completed the early brachytherapy, or high-dose radiation, phase of my treatment, I must thank the involved healthcare workers profoundly. After the daunting prospect of general anesthetic, 16 catheters inserted into my prostate and a radiation-tipped wire inserted into each of the catheters to treat the cancer present, I woke about two hours later to a friendly nurse who gave me a snack while I woke up and then escorted me as I walked to my waiting wife and a ride home. Three days after, there was minimal evidence of pain or sensitivity and I am off to visit friends today. The whole experience at the General Hospital Cancer Centre was amazing with friendly engagement and information as to what was happening at every step of the way. So yes, Mohammed, people should not be afraid, but early detection saves you and our healthcare system discomfort and cost. All you have to fear is fear is fear itself. I was, or hope to be, one of the lucky ones. Michael Wiggin is an Ottawa resident.
